Albany, NY -- (SBWIRE) -- 12/17/2018 -- DelveInsight has announced the addition of the "Acute Kidney Injury - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Acute Kidney Injury for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Acute Kidney Injury forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Request for sample pages

Acute Kidney Injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. It causes a build-up of waste products in blood and makes it hard for kidneys to keep the right balance of fluid in the body. AKI can also affect other organs, such as the brain, heart, and lungs. This disease is common in patients who are in the hospital, in intensive care units, and especially in older adults. The symptoms of AKI include: not enough urine, swelling in legs, ankles or feet, feeling tired, trouble in catching the breath, feeling confused, nausea and pain or pressure in the chest. Male-to-female ratios of AKI patients differ among various countries, but female excess is a consistent finding.

DelveInsight estimates that there were around 1,516,000 incident cases of AKI in 2016 in 7MM. These Incident cases are further expected to increase by 2027. United States accounts for the highest Incident population of Acute Kidney Injury followed by EU5 and Japan. Among the EU5 countries, Germany had the highest incident population of AKI with 149, 000 cases in 2016. Acute Kidney Injury related hospitalization is less in Japan in comparison to other 7MM and reported incidence was around 44,000 cases in 2016. Stage II (KIDGO staging) AKI corresponds to the relatively higher diagnosed discharge population with approximately 346,000 cases in 2016. AKI is common, especially among the elderly (? 65). It has been estimated that it occurs during 2–7% of all hospital admissions and at even higher rates in elderly patients.

Market analysis carried out for the period of 2016-2027 shows the market size of Acute Kidney Injury (AKI) was around USD 4.3 Billion in 2016 in the 7MM. There is no cure for AKI and the current treatment is aimed at managing the underlying cause and prognosis of AKI. Conventional therapies, such as drugs to manage blood pressure, fluid overload and cardiac output, to stabilize hemodynamic and oxygenation parameters, glycemic control, nutritional support to reduce the severity of AKI are frequently used in manageable cases of AKI whereas in critically ill patients RRT therapies are recommended. In the current scenario, market persists with various unmet needs related to diagnosis and effective treatments which include lack of approved therapies for Sepsis AKI, and high affordability. Also, various companies are working on the development of many new therapies with a novel mechanism of action to tackle the unmet need. Eight potential therapies focused mainly on risk factors modifiers (e.g. sepsis, cardiac surgery) and delayed graft function are expected to enter the AKI market in the forecast period (2018-2027).

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies
1. Angion Biomedica
2. Quark Pharmaceutical
3. AM Pharma
4. Sentien Biotechnologies
And many others

Drugs covered
1. BB3
2. QPI1002
3. Reltecimod
4. recAP
5. SBI-101
And many others

Report Scope
The report covers a descriptive overview of the Acute Kidney Injury, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Acute Kidney Injury and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Acute Kidney Injury is provided, along with an assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Acute Kidney Injury market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Kidney Injury market